MTOR and central nervous system cancer: Our result revealed that the protein levels of IGF1R, IRS1, mTOR, and Bcl‐2 were increased in TMZ‐resistant glioma cells (U87‐TR and SF295‐TR) compared with TMZ‐sensitive glioma cells (U87 and SF295) (Fig. 3D).